ChunLab, Inc. Overview
| Metric | FY2023 | FY2024 | FY2025 | H1-2026 |
|---|---|---|---|---|
| Employees (headcount, period-end) | — | — | 124 | 83 |
Note: the FY2025 column holds the end-June 2025 figure (124), as reported in a CJ affiliate headcount comparison.
CJ Bioscience is the red-biotechnology (pharmaceutical and healthcare) arm of CJ CheilJedang. It was built on ChunLab, a Seoul National University spin-out that pioneered microbial genomics and bioinformatics. Its core intellectual capital is a precision microbial taxonomy platform (EzBioCloud, now the AI-augmented Ez-Mx platform), large Korean human-microbiome datasets, a strain library, and the discovery platforms (MicroRx, MicroDx) and candidates acquired from the UK's 4D pharma in 2023.
From 2022 to 2025 the company positioned itself as a microbiome-therapeutics developer. Its lead asset, CJRB-101, an oral live biotherapeutic tested with pembrolizumab, was voluntarily terminated after Phase 1 in May 2026. Management has since rebalanced toward "Health & Wellness": personalised gut-microbiome testing and precision-nutrition solutions linked to CJ's health-functional-food business, alongside earlier-stage drug programmes (CJRB-201, CJRB-302, CJRB-401). Revenue is under KRW 4 bn a year against R&D spending above KRW 20 bn. The company depends on parent funding and faces tightening KOSDAQ listing-maintenance thresholds.
What the company does
CJ Bioscience works in two connected areas.
Microbial bioinformatics platform and solutions. This is the original ChunLab business. ChunLab built a genome-based, high-resolution microbial reference database and cloud analysis environment, EzBioCloud. It offered next-generation sequencing (NGS) analysis services, bioinformatics software (CLcommunity, CLgenomics), and a "NGS/BI total solution" for academic, government and industrial customers.
At the time of the IPO (2019), the company described its microbiome reference database as cited more than 8,500 times in the global literature. It also reported:
-
more than 120,000 human-microbiome data sets;
-
more than 5,924 novel taxa identified through its Precision Taxonomy Platform (as of August 2019).
In 2019 it launched the beta version of TrueBac ID, described as the first genome-based solution for bacterial identification in infection diagnostics. At that time it was pursuing FDA clearance for TrueBac ID as Software as a Medical Device (SaMD).
Microbiome-based healthcare and therapeutics. This includes:
-
consumer and clinical gut-microbiome monitoring (Smilebiome; the Pibio app-linked personalised probiotic service launched around 2020; and the "Smile Gut" (스마일 것) gut-microbiome test referenced by management in 2025);
-
since 2022, a drug-discovery pipeline of live biotherapeutic products (LBPs).
After the CJ acquisition, CJ CheilJedang folded its existing red-bio assets (strain library, fermentation know-how, therapeutics research) into the company in January 2022.
Revenue model
| Revenue type (latest disclosed mix, Q2-2026) | Share of revenue (%) |
|---|---|
| Microbial bioinformatics platform & solutions (services/subscriptions/analysis) | 86 |
| Microbiome-based healthcare (testing/consumer solutions) | 14 |
| Licensing / milestone income | 0 |
| Therapeutic product sales | 0 |
Revenue is almost entirely service and solution revenue:
-
microbial genome analysis and bioinformatics solutions;
-
microbiome-based personalised healthcare services.
Industry press summarising DART filings consistently describes revenue this way. A market-data summary of the Q2-2026 disclosure gives the revenue split as:
-
"microbial bioinformatics platform and solutions": 86%;
-
"microbiome-based healthcare": 14%.
No product-sale revenue from approved therapeutics exists. No licensing (technology-transfer) revenue has been recognised: the 2024 target of three technology-out deals by 2026 had not been met as of October 2026.
Source: Butler.works summary of company disclosures (Q2-2026 revenue basis).
Value chain position
The company sits upstream in the microbiome value chain, covering:
-
reference data, strain identification and taxonomy;
-
multi-omics analytics and biomarker discovery (Ez-Mx);
-
candidate discovery (Ez-Mx combined with 4D pharma's MicroRx);
-
early clinical development.
It does not own GMP manufacturing for live biotherapeutics. At the IPO stage it had arranged CMO/CDMO cooperation with GC Green Cross (2019 MOU). In the wellness channel, it supplies science (testing, strain evidence, precision-nutrition algorithms). Consumer product commercialisation sits with group affiliates, notably CJ Wellcare, CJ CheilJedang's health-functional-food subsidiary formed in 2022.
Customer types and end-markets
| Customer type | Offering | End-market |
|---|---|---|
| Academic and government research institutes | EzBioCloud, NGS/BI analysis, national R&D projects | Life-science research tools & services |
| Public-sector tenders | Microbial genome analysis | Government bioinformatics procurement (affected after CJ affiliation; see 2.5) |
| Hospitals and clinics | Gut-microbiome analysis services (e.g., Mediram Korean Medicine Hospital, Sun Medical Center, BeautyOn Clinic) | Clinical/precision health |
| Consumers (direct or via partners) | Smilebiome, Smile Gut testing, personalised nutrition (MAC solution planned H2-2026) | Consumer wellness / precision nutrition |
| Pharma / biotech (target) | Licensing of LBP candidates and platform | Microbiome therapeutics |
| Group affiliates (CJ CheilJedang, CJ Wellcare) | Strain/microbiome science for health-functional foods | Probiotics / functional foods |
Company's own characterisation versus independent characterisation
Company's description. Recent company language (2024 vision; 2025–2026 disclosures and press releases) has evolved:
-
At launch (Jan 2022): "Global No.1 microbiome company".
-
2024 vision: "A global innovator in healthcare through AI-powered microbiome science", with the mission "Contributing to global health with ONLYONE therapeutics and solutions".
-
After the May 2026 termination of CJRB-101: the company says it will pursue drug development and a premium wellness business in parallel. It aims to strengthen a profitability- and cash-flow-centred structure based on validated strain assets and clinical data, building a microbiome-based "Health & Wellness" business. (Paraphrased from the company statement accompanying the 12 May 2026 disclosure.)
Independent characterisation. CJ Bioscience is best described as a subscale microbiome bioinformatics service company carrying a parent-funded R&D programme whose most advanced clinical asset has now been discontinued. The facts behind this view:
Revenue fell after the acquisition: Revenue declined from about KRW 5.3 bn (2020, pre-acquisition) to KRW 3.5–3.7 bn (2024–2025). Management attributed part of this to losing preferential access to public tenders once the company became a large-business-group affiliate rather than an SME.
Revenue is far below spending: R&D expense of KRW 19–23 bn a year has run at roughly 4–7 times revenue.
The strategic logic now rests on wellness: The company is converting its microbiome science into consumer and clinical wellness revenue inside the CJ ecosystem. That is lower-risk but also lower-value than the original licensing thesis.
Strategy
Evolution of stated strategy
| Period | Stated vision / themes | Quantitative targets | Outcome |
|---|---|---|---|
| IPO (2019) | Global expansion of bioinformatics platform; microbiome diagnostics and therapeutics; "test–diagnose–treat–manage" total healthcare | Not quantified | Platform revenue stagnated |
| Launch (Jan 2022) | "Global No.1 microbiome company." Three innovation-growth strategies: (1) ultra-gap R&D (cohorts, global microbiome big data, bio-digital platform); (2) bio-digital-platform-based drug development; (3) global expansion of new businesses (NGS, genomic diagnostics, CDMO, personalised health-functional food) | 10 pipelines and 2 technology-outs by 2025; US FDA Phase 1 entry within 2–3 years | 15 pipelines reached (2023); FDA Phase 1 achieved (2023); 0 technology-outs |
| New Vision (Jun 2024) | "A global innovator in healthcare through AI-powered microbiome science"; AX (digital-to-AI transformation); synergy with CJ CheilJedang foods and health-functional foods | 3 technology-outs by 2026 (CJRB-101, CJRB-201, CJRB-302) | Lead asset CJRB-101 terminated May 2026; target widely assessed as unachievable |
| Post-termination (May 2026 onward) | Parallel pursuit of drug development and premium wellness; profitability- and cash-flow-centred structure; "Health & Wellness" based on validated strains and clinical data | MAC personalised solution launch in H2-2026 | In progress |
Strategic initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Description | Status |
|---|---|---|---|
| Parent-funded recapitalisation | Dec 2024 | KRW 40 bn placement to CJ CheilJedang to fund CJRB-101 and follow-on pipeline and the AI microbiome platform business | Completed |
| Leadership transition | Jul–Aug 2025 | Commercially oriented pharma executive (Yoon) replaces scientist-founder | Completed |
| Clinical-network wellness rollout | Jan–Mar 2026 | Gut-microbiome analysis at Mediram Korean Medicine Hospital; MOU with Sun Medical Center; skin–gut joint research MOU with BeautyOn Clinic | Ongoing |
| Korean microbiome reference assets | Jan–Feb 2026 | Life-cycle gut-microbiome map; scientific evidence for personalised dietary solutions | Published |
| Pipeline rebalancing | May 2026 | CJRB-101 terminated; clinical data and know-how to be applied to follow-on programmes | Completed |
| Precision-nutrition platform | Jun 2026 | Ez-Mx + DIGEST/DIGEST-Flow + 186-person human study + ML prediction; target applications include gut health, GLP-1 side-effect mitigation and metabolic disease | Disclosed |
| MAC personalised solution | H2-2026 (planned) | Product commercialisation from MAC human-application study | Launch not confirmed in sources as of 19 Oct 2026 |
| Cost reduction | 2025–2026 | Headcount down ~33% YoY to 83; H1-2026 operating loss down 13% | Ongoing; no formal cost target disclosed |
Parent context. On 1 July 2026, CJ CheilJedang reorganised into three divisions: Lifestyle Food, Technology Materials and Core Materials. Coverage in 2024–2026 links CJ CheilJedang's portfolio review (including a reported exploration of a green-bio sale in Nov 2024) to CJ Bioscience's funding outlook.
ESG commitments. None specific to CJ Bioscience were identified.
Medium-term guidance
No numerical revenue or profit guidance has been published. The only quantified medium-term goal, three technology-outs by 2026, has effectively lapsed.
The binding external constraints are the KOSDAQ listing-maintenance thresholds:
Pre-tax loss test: pre-tax continuing loss exceeding 50% of equity in two of the last three years.
Revenue floor: currently KRW 3 bn.
Tightening revenue floor: the Financial Services Commission plans to raise it to KRW 5 bn in 2027 and KRW 10 bn in 2029 (as reported by IB Tomato, Apr 2025).
Products & Services
Microbial bioinformatics platform & solutions
| Product / platform | Description and capabilities | Target customer | Launch / latest | Pricing model |
|---|---|---|---|---|
| EzBioCloud | Genome-based microbial reference database and cloud bioinformatics service for taxonomic identification and microbiome profiling. ChunLab's flagship; its reference database had 8,500+ literature citations by 2019. | Academic, government and industry microbiology labs worldwide | Pre-2019; ongoing | Not disclosed (historically web/cloud service; analysis-based fees) |
| Precision Taxonomy Platform | Proprietary high-resolution taxonomic classification combining BT/IT. By Aug 2019 it had identified 5,924+ novel taxa. Underpins diagnostics and candidate discovery. | Internal; partners | 2019 disclosure | — |
| Ez-Mx platform (이지엠) | AI-augmented microbiome biomarker and precision-analysis platform. Species-level resolution claimed to exceed public databases. Used for drug-candidate discovery and Korean gut-microbiome typing. | Internal R&D; wellness partners | Referenced 2023; enhanced under 2024 AI vision | — |
| NGS/BI total solution | End-to-end sequencing plus bioinformatics analysis service | Research institutes, public projects | Pre-2019 | Project-based |
| CLcommunity | Microbiome data analysis software (listed as main product in Korean registries) | Researchers | Pre-2019 | Licence (not disclosed) |
| CLgenomics | Microbial genome analysis software | Researchers | Promoted 2014 | Licence (not disclosed) |
| TrueBac ID | Whole-genome-based bacterial identification for infection diagnosis. Beta launched Sep 2019; FDA SaMD pathway pursued at IPO. | Clinical microbiology labs | Beta 2019 | — |
| COVID-19 variant analysis platform | Rapid (claimed ~10-minute) transmission-path and variant analysis of SARS-CoV-2 genomes (ChunLab-era press) | Public health / researchers | ~2020–2021 | — |
| MicroDx (acquired from 4D pharma) | Microbiome-profiling-based diagnostics platform | Internal | Acquired Mar 2023 | — |
Microbiome-based healthcare and wellness
| Product / service | Description | Target customer | Launch / latest | Pricing model |
|---|---|---|---|---|
| Smilebiome (스마일바이오미) | Human-microbiome monitoring service | Consumers / clinics | Pre-2019 | Test-based (not disclosed) |
| Personalised microbiome healthcare service with Pibio app | Three-step model: diagnose microbiome (questionnaire or lab analysis), prescribe customised probiotics, track changes via app. The company said three common microbiome types exist in Korea. | Consumers | ~2020 | — |
| Smile Gut (스마일 것) gut-microbiome test | Gut-microbiome testing service cited by management (2025) as a new revenue source | Consumers, clinics | Referenced 2025 | — |
| Clinical gut-microbiome analysis service | Deployed with partner institutions: Mediram Korean Medicine Hospital (Jan 2026); Sun Medical Center MOU (Jan 2026); BeautyOn Clinic Dolgoji skin–gut research MOU (Mar 2026) | Hospitals/clinics | 2,026 | B2B (not disclosed) |
| Korean life-cycle gut-microbiome map | Reference atlas of Korean gut microbiome across life stages, supporting personalised products | Internal / partners | Announced 19 Jan 2026 | — |
| Microbiome-friendly diet score | Model predicting gut-microbiome/diet correlations; based on 543 Korean subjects' data | Wellness product design | IHMC Jun 2026 | — |
| DIGEST / DIGEST-Flow (patent pending) | In-vitro gut-simulation platform reproducing digestion and gut microbial ecology to test foods or functional ingredients. In a 186-person dietary intervention trial, the in-vitro predicted microbial shifts were mirrored in humans (company claim). | Internal; food/supplement partners | Disclosed Jun 2026 | — |
| ML response-prediction model | Predicts individual responses to foods or nutrition solutions; ROC-AUC 0.85 reported | Internal | Jun 2026 | — |
| Personalised "MAC" solution | Precision-nutrition product based on MAC human-application study; planned commercial launch in H2-2026. Launch not yet confirmed as of 19 Oct 2026 in sources reviewed. | Consumers | Planned H2-2026 | — |
Therapeutics pipeline (live biotherapeutic products)
| Programme | Modality / origin | Indication | Status (Oct 2026) | Notes |
|---|---|---|---|---|
| CJRB-101 | Oral LBP. Strain derived from fermented-food Leuconostoc mesenteroides, from CJ's strain library and listed on EFSA's safety list. Reported mechanism: TLR4 agonism / immune activation. | Advanced or metastatic NSCLC, HNSCC, melanoma (with pembrolizumab), including checkpoint-inhibitor-refractory patients | Terminated after Phase 1 (disclosed 12 May 2026). Phase 2 not pursued. | Phase 1 planned up to 46 patients; Phase 2 up to 120. Sites: Severance, Samsung Medical Center, UC Irvine, Univ. of Pittsburgh. Lead investigator Prof. Cho Byoung Chul (Yonsei). |
| CJRB-201 | LBP (in-house) | Inflammatory bowel disease (IBD) | Preclinical | Jun 2026 preclinical data: mucus-barrier maintenance, epithelial recovery, energy-metabolism gene expression; weight-loss, inflammation and tissue-damage improvements in animals |
| CJRB-302 | LBP (likely 4D-derived; origin not confirmed) | Parkinson's disease / degenerative brain disease | Preclinical / early | Named as a 2024 technology-out target |
| CJRB-401 | LBP | Asthma | Early stage | Listed as active by company in May 2026 |
| 4D pharma-derived assets (9 candidates acquired) | Single-strain LBPs from MicroRx | Solid tumours, IBD, IBS, asthma, Parkinson's | Status by asset not disclosed | Pre-acquisition 4D assets included MRx0518 (immuno-oncology) and MRx0005/MRx0029 (Parkinson's; FDA IND cleared under 4D). Whether CJ is advancing these specific codes is not disclosed. |
| CLCC1 | ChunLab-era candidate from Precision Taxonomy Discovery Platform | Hepatocellular carcinoma (monotherapy); colorectal cancer (co-administration) | Animal efficacy shown (2020); current status not disclosed | Not listed in post-2023 pipeline summaries reviewed |
| Legacy programmes | Microbiome combinations | Combination oncology, NASH, autism spectrum disorder | Research-stage at IPO (2019); current status not disclosed | — |
Pipeline count history:
-
15 programmes in July 2023 (4 in-house plus 11 from 4D);
-
15 programmes in June 2024, of which 7 had moved beyond the earliest discovery stage per company commentary.
A post-termination pipeline count was not disclosed.
Financial Narrative
Sources: DART annual reports as summarised by Dealsite (FY2022 preliminary disclosure, 14 Feb 2023), Medigate News, Dailypharm, CEO Score Daily, Dealsite (FY2025), Butler.works and ChickStock. Consolidated K-IFRS; fiscal years ending 31 December.
Income statement
Notes:
-
FY2021 growth uses FY2020 revenue of KRW 5.3 bn.
-
FY2023 and FY2024 growth rates are derived; FY2022 and FY2025 rates are as reported.
-
TTM EPS to H1-2026 is reported by a data vendor at KRW -1,707.
-
No dividends have been paid since listing (accumulated deficit; loss-making).
Margins (derived, %)
Revenue CAGR FY2021–FY2025 (derived): about -4.2% per year (KRW 4.4 bn to KRW 3.7 bn). Over FY2020–FY2025 (KRW 5.3 bn to KRW 3.7 bn), the CAGR is about -6.9% per year.
Interim results 2025–2026
Notes:
-
Q1-2025 revenue is derived from the reported 14.2% YoY decline to KRW 0.783 bn in Q1-2026.
-
Q2-2026 figures are derived as H1 less Q1 (vendor calculation).
-
H1-2026 operating loss narrowed 13% YoY, consistent with the headcount reduction (124 to 83) and the wind-down of CJRB-101.
Earlier interim reference points:
-
Q1-2024 operating loss: KRW 7.8 bn.
-
9M-2023: revenue KRW 4.1 bn (+59% YoY) and operating loss KRW 25.0 bn (versus KRW 20.7 bn).
Balance sheet
Additional disclosed or derived data points:
Cash: cash plus short-term financial instruments fell to KRW 38.7 bn at end-Q3 2023, before the Q3-2023 rights proceeds settled and the Dec 2023 building sale (KRW 33.1 bn).
Equity at H1-2026 (derived): BPS of KRW 3,195 times about 13.3 m shares outstanding gives roughly KRW 42.5 bn. Shares outstanding are derived from KRW 49.5 bn market cap divided by the KRW 3,720 share price.
Shares outstanding reconciliation (derived): about 5.85 m shares post-Oct-2021, plus 3.23 m (2023 rights), plus 3.95 m (Dec-2024 placement), gives about 13.0 m shares. This is consistent with market-data share counts.
Liquidity: a market-data vendor describes liquidity as adequate but interest coverage as absent.
Cash flow: notes and sources
Note: buybacks are shown as 0 because no buyback programme was identified.
R&D expense
Pre-acquisition R&D ran at "around KRW 5 bn" a year (Dailypharm). FY2023 % of revenue is derived. H1-2025 R&D was KRW 9.2 bn (543% of revenue). Q1-2026 R&D was KRW 3.3 bn, more than four times revenue.
Ratios
Notes:
-
ROE is taken from a market-data vendor using latest reported equity. TTM ROE to H1-2026 is -53.4%.
-
EBITDA is negative, so net debt/EBITDA and interest coverage are not meaningful.
Commentary on trends, inflections and drivers
Revenue. Revenue has not recovered to its pre-acquisition level (KRW 5.3 bn in FY2020). Management gave two explanations for the FY2022 decline:
Loss of SME status: As an SME, ChunLab could win pharma-biotech public tenders on a preferential basis. As a CJ affiliate (large business group), it became largely ineligible.
Management focus: Resources were redirected toward drug discovery.
FY2023's rebound to KRW 5.6 bn did not persist: FY2024 fell to KRW 3.5 bn, close to the KOSDAQ KRW 3 bn revenue threshold. FY2025 recovered modestly to KRW 3.7 bn. H1-2026 was flat at KRW 1.68 bn. Q1-2026 fell 14.2% YoY; Q2-2026 rose 14.5%.
Operating losses. Losses tripled after the acquisition, from KRW 10.1 bn in FY2021 to KRW 32–34 bn in FY2022–FY2024. The drivers were:
-
non-clinical studies;
-
FDA IND preparation;
-
academic collaborations (e.g., Harvard);
-
specialist hiring;
-
from late 2023, two-country clinical operations for CJRB-101.
FY2025 marked the first meaningful contraction, to KRW 24.8 bn (27.5% narrower). This coincided with Phase 1 enrolment completing in March 2025 and the leadership change in August 2025. H1-2026 losses narrowed further, to KRW 11.7 bn.
Net income versus operating income.
-
FY2021 net loss (KRW 19.3 bn) exceeded the operating loss (KRW 10.1 bn), implying sizeable non-operating charges around the change of control.
-
FY2023 net loss (KRW 22.9 bn) was smaller than the operating loss (KRW 32.1 bn), consistent with a non-operating gain, plausibly the December 2023 building sale. That gain is not confirmed in sources reviewed.
Funding pattern. The company has relied on:
-
the 2021 CJ subscription (KRW 73.2 bn);
-
the 2023 rights offering (KRW 45.6 bn);
-
the 2023 building sale to the parent (KRW 33.1 bn);
-
the 2024 parent placement (KRW 40.0 bn);
-
in 2025, rising short-term borrowings.
The accumulated deficit reached KRW 143.3 bn by end-2025. Asia Today (May 2026) reported that CJ CheilJedang has committed about KRW 160 bn to the company in total since 2021.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment (Revenue Share, %) Overview
| Segment (revenue share, %) | Q2-2026 |
|---|---|
Microbial bioinformatics platform & solutions (% of revenue) | 86 |
Microbiome-based healthcare (% of revenue) | 14 |
Revenue by Segment
| Segment (revenue, KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total company revenue (KRW Bn) | 5.6 | 3.5 | 3.7 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 4.4 | 4.07 | 5.6 | 3.5 | 3.7 |
Revenue growth YoY (%) | -17.0 | -6.6 | 37.6 | -37.5 | 6.5 |
Operating income (KRW Bn) | -10.1 | -33.2 | -32.1 | -34.2 | -24.8 |
Net income (KRW Bn) | -19.3 | -34.9 | -22.9 | -32.8 | -24.0 |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating margin (%) | -230 | -816 | -573 | -977 | -670 |
Net margin (%) | -439 | -857 | -409 | -937 | -649 |
Income Statement
| Metric | Q1-2025 | H1-2025 | Q1-2026 | Q2-2026 | H1-2026 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 0.91 | 1.68 | 0.78 | 0.90 | 1.68 |
Operating income (KRW Bn) | — | -13.55 | -5.3 | -6.4 | -11.74 |
Net income (KRW Bn) | — | — | — | -6.2 | — |
R&D expense (KRW Bn) | — | 9.2 | 3.3 | — | — |
Key Financials
| Metric | FY2021 | FY2022 | FY2025 |
|---|---|---|---|
Cash & equivalents + short-term financial instruments (KRW Bn) | 80.0 | 49.3 | — |
Retained earnings / accumulated deficit (KRW Bn) | — | — | -143.3 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW Bn) | — | — | — | — | -23.4 |
Dividends paid (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Equity raised (KRW Bn) | 73.2 | 0 | 45.6 | 40.0 | 0 |
Asset disposals – HQ building (KRW Bn) | 0 | 0 | 33.1 | 0 | 0 |
Key Financials and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
R&D expense (KRW Bn) | 18.9 | 22.5 | 23.0 |
R&D as % of revenue (%) | 464 | 402 | 663 |
Returns & Leverage Ratios (%)
| Ratio | FY2025 |
|---|---|
ROE (%) | -53.5 |
Revenue by Region
| Region (revenue, KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total (KRW Bn) | 5.6 | 3.5 | 3.7 |
Share Price & Returns
| Reference | Date | Price (KRW) |
|---|---|---|
IPO price | Dec 2019 | 40,000 |
CJ secondary purchase price | Jul 2021 | 40,000 |
CJ new-share subscription price | Jul 2021 | 37,465 |
Close before rights announcement | 22 May 2023 | 30,650 |
Rights offering final price | Aug 2023 | 14,110 |
Pre-rumour close | 18 Nov 2024 | 8,750 |
Limit-up close (bio sale rumour) | 20 Nov 2024 | 14,780 |
Third-party allotment price | Dec 2024 | 10,119 |
52-week high | 22 Dec 2025 | 10,200 |
Post-IHMC trading | 5 Jun 2026 | 3,655–3,980 |
52-week low | 30 Jul 2026 | 3,060 |
Latest close | 19 Oct 2026 | 3,720 |
Capital Markets
| Metric | 5-year | Since IPO |
|---|---|---|
Share price change (%) | -90.7 | -90.7 |
Market Valuation
| Metric | FY2020 | FY2023 | FY2026 |
|---|---|---|---|
Market capitalisation (KRW Bn) | 185.2 | 180.2 | 49.5 |
Valuation Multiples
| Multiple | CJ Bioscience | Industry median (vendor peer set) |
|---|---|---|
P/E | -2.22x (n.m.) | — |
P/B | 1.19x | 1.26x (34 companies) |
P/S | 13.38x | 3.01x (34 companies) |
EV/EBITDA | n.m. (negative EBITDA) | — |
Share Count (millions) and Returns & Leverage Ratios
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
New shares issued (millions) | 1.95 | 0 | 3.23 | 3.95 | 0 |
Gross equity proceeds (KRW Bn) | 73.2 | 0 | 45.6 | 40.0 | 0 |
Analyst Conclusions
Management guidance
No numerical guidance. Management's stated priorities after May 2026 are:
-
parallel drug development (CJRB-201 IBD, CJRB-302 Parkinson's, CJRB-401 asthma, 4D-derived assets);
-
a premium wellness business built on validated strains and clinical data;
-
a profitability- and cash-flow-centred structure;
-
product launch of the personalised MAC precision-nutrition solution in H2-2026.
Consensus growth expectations
None available (no sell-side coverage identified).
Bull case
-
Wellness monetisation via CJ channels. The precision-nutrition stack (Ez-Mx, DIGEST, 186-person validation, ROC-AUC 0.85 prediction model) plus CJ Wellcare's established probiotic brand and online export channels could lift revenue above the KRW 5 bn (2027) threshold with modest unit volumes. Revenue is so small (KRW 3.7 bn) that even a KRW 2–3 bn wellness contribution would be a large percentage gain.
-
Cost reset drives loss narrowing. Operating losses have already fallen from KRW 34.2 bn (FY2024) to KRW 24.8 bn (FY2025) and to KRW 11.7 bn in H1-2026. With CJRB-101 clinical costs gone and headcount at 83, a run-rate loss near or below KRW 20 bn reduces funding needs and dilution.
-
Option value in preclinical assets and platforms. CJRB-201 (IBD) preclinical data and 4D-derived assets could attract partners in a sector seeing renewed interest (Celltrion–KoBioLabs, Jul 2026). At KRW 49.5 bn market cap and about 1.2x book, little value is ascribed to the pipeline.
Bear case
-
Listing-maintenance squeeze. Revenue of KRW 3.5–3.7 bn sits barely above today's KRW 3 bn floor and well below the KRW 5 bn (2027) and KRW 10 bn (2029) thresholds. Continued losses near half of equity (about KRW 42.5 bn derived) could trigger management-issue designation.
-
Parent fatigue. CJ CheilJedang has put in about KRW 160 bn since 2021 with no technology-out and a terminated lead asset, while its own bio profits collapsed in 2026. Further support may come only on dilutive or restructuring terms (e.g., merger into an affiliate, privatisation or wind-down of drug R&D).
-
Commoditised wellness market. Personalised gut testing and probiotics are crowded, low-barrier categories where several Korean microbiome firms are pursuing the same pivot. Scientific differentiation may not translate into pricing power, leaving the company with neither a drug franchise nor a scaled consumer business.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
| Commercial launch of personalised MAC solution | H2-2026 (by Dec 2026) | First test of wellness revenue model |
| FY2026 business report (revenue vs KRW 3 bn floor; loss vs equity) | ~Mar 2027 | Listing-maintenance compliance; FY2027 KRW 5 bn threshold looming |
| Funding actions (new equity, parent loans, asset sales) | Any time | Dilution and parent-commitment signal |
| Pipeline updates on CJRB-201 / -302 / -401 and 4D assets; any partnering | 2026–2027 | Residual drug-development value |
| Peer-reviewed publication or full presentation of CJRB-101 Phase 1 data | 2026–2027 | Validation of the strain for wellness or future use |
| CJ CheilJedang portfolio decisions (bio division, CJ Wellcare integration) | Ongoing | Determines strategic home and funding of CJ Bioscience |
| Clinic partnership expansion and B2B testing volumes | Quarterly | Revenue traction indicator |
| Headcount and R&D run-rate in Q3/Q4-2026 reports | Nov 2026; Mar 2027 | Confirms cost reset |
Analyst verdict
ChunLab entered public markets in 2019 as a credible scientific franchise. Its microbial reference data and taxonomy tools were widely used in academia, and it promised to turn that data advantage into diagnostics and drugs. CJ CheilJedang's 2021 acquisition, for about KRW 98 bn at KRW 37,465–40,000 per share, was a bet that group capital could accelerate the move from data to therapeutics.
Five years on, the outcome is clear in the numbers:
-
revenue has drifted down to KRW 3.7 bn;
-
annual operating losses of KRW 25–34 bn have produced an accumulated deficit of KRW 143 bn;
-
three rounds of equity issuance have been priced progressively lower;
-
the company's only clinical asset, CJRB-101, was withdrawn after Phase 1 in May 2026.
The share price, at KRW 3,720, is down more than 90% from the IPO and acquisition reference prices.
The current strategy is a rational retrenchment. Management is redeploying the company's genuine assets into precision nutrition and clinic-based testing, where CJ's consumer channels give it a route to market: Korean microbiome data, the Ez-Mx analytics platform, the DIGEST gut-simulation system and a growing human-study evidence base. Costs are falling quickly; H1-2026 operating losses were 13% lower year on year with a third fewer staff.
The constraint is time. KOSDAQ revenue thresholds rise to KRW 5 bn in 2027 and KRW 10 bn in 2029, and the parent is under its own earnings pressure.
Our assessment is that CJ Bioscience is now best analysed as a parent-dependent strategic option rather than a stand-alone investment case. Its equity value (about KRW 50 bn, roughly 1.2x book) mainly reflects residual platform and IP value plus the expectation of continued CJ support. The decisive monitorables are:
-
whether the H2-2026 MAC launch and clinic partnerships produce measurable revenue;
-
whether CJ CheilJedang continues to fund the company or restructures it.
Absent visible wellness traction by the FY2026 results, the risk of further dilution or corporate restructuring outweighs pipeline upside.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background |
|---|---|---|---|
Yoon Sang-bae (윤상배) | CEO (Representative Director) | Since 14 Aug 2025 (designated 8 Jul 2025) | Born 1970. BS and MS in Pharmacy, Chung-Ang University; MBA, KAIST. Career: Chong Kun Dang, Samsung C&T (bio business), GSK Korea, Dong-A ST, Boryung (~6 years, 2016–2021 period), then CEO of Huons (2022–2024). At Huons, consolidated revenue grew from KRW 492.4 bn (2022) to KRW 590.2 bn (2024). Received a presidential commendation on Mid-sized Enterprise Day (2024). |
Chun Jongsik (천종식) | Adviser (R&D advisory, external networking); former founder-CEO | CEO Dec 2009 – Aug 2025 | Founder; former Professor, School of Biological Sciences, Seoul National University (~20 years). Resigned professorship in Jan 2022 to run CJ Bioscience full-time. Led CJRB-101 into multinational Phase 1/2 and the 4D pharma asset acquisition. |
Shin Chang-sik (신창식) | Head, Drug Research Group | — | Presented pipeline at IHMC 2026 industry session |
Lee Je-hee (이제희) | Senior Manager, Wellness Research Group | — | Presented precision-nutrition platform at KMB 2026 |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change | Context |
|---|---|---|
29 Dec 2021 | CJ nominees appointed to board; Chun retained as CEO | Post-acquisition integration |
8 Jul 2025 | Yoon Sang-bae designated CEO | Company cited need for leadership to "leap a step" and execute drug-development strategy; also referenced premium health-functional-food ambitions |
14 Aug 2025 | Yoon formally appointed; Chun becomes adviser | Single-CEO structure |
Major Shareholders
| Holder | Stake (%) | Date / basis |
|---|---|---|
CJ CheilJedang Corp. | 61.95 | As reported Jul 2025 (after Aug-2023 rights at 120% take-up and Dec-2024 KRW 40 bn placement) |
Chun Jongsik (founder) | 6.65 | — |
Free float (approximate, derived) | ~30 | 100% less CJ stake and founder stake (if unchanged) |
Competitive Landscape
Key Competitors
| Competitor | Country | Positioning relative to CJ Bioscience |
|---|---|---|
Seres Therapeutics | US | Developed SER-109 (VOWST), the first oral microbiome therapeutic, FDA-approved in Apr 2023. Commercial-stage precedent. |
Ferring Pharmaceuticals (Rebyota) | Switzerland | First approved microbiome therapeutic (rectal); limited uptake reported |
Vedanta Biosciences | US | — |
MaaT Pharma | France | — |
KoBioLabs (고바이오랩) | Korea | KGLP-007 in Phase 2 for ulcerative colitis (from 2021); licensed 3 candidates to Celltrion (Jul 2026); building health-functional-food revenue |
Genome & Company (지놈앤컴퍼니) | Korea | Immuno-oncology microbiome programmes with Merck/MSD (Phase 2, 2023). Acquired US CDMO List Labs (60% for USD 27 m; ~KRW 10 bn annual revenue at acquisition). Cosmetics and supplements revenue (KRW 2.2 bn in 2023, 15.6% of revenue). |
Enterobiome; Cell Biotech (쎌바이오텍) | Korea | Microbiome drug developers pivoting to functional-food and cosmetics revenue |
Macrogen | Korea | Large NGS service provider; launched a microbiome business headquarters |
Psomagen (Macrogen affiliate, KOSDAQ-listed) | US/Korea | NGS services; listed by Owler as a ChunLab competitor |
GENEWIZ (Azenta) | US | Global sequencing services |
QIAGEN (microbial genomics software); One Codex; CosmosID | Global | — |
Peer Comparison FY2025
| Metric | CJ Bioscience | KoBioLabs | Genome & Company |
|---|---|---|---|
Latest revenue | KRW 3.7 bn (FY2025) | — | — |
Revenue growth | +6.5% (FY2025) | — | — |
Operating margin | ~-670% (FY2025, derived) | — | — |
R&D intensity | 663% of revenue (FY2024) | — | — |
Most advanced asset | Preclinical (after CJRB-101 termination) | Phase 2 (UC) | Phase 2 (IO) |
Market cap (Oct 2026) | ~KRW 49.5 bn | — | — |
Recent Developments
Sector context during the window: * In July 2026, Celltrion in-licensed three microbiome candidates from KoBioLabs. This is a signal of renewed large-pharma interest in Korean microbiome assets, but it does not involve CJ Bioscience.



